Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy-Reference-Cited by-同舟云学术

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

Published:2008-01 Issue:1 Volume:14 Page:28-36
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Buckanovich Ronald J,Facciabene Andrea,Kim Sarah,Benencia Fabian,Sasaroli Dimitra,Balint Klara,Katsaros Dionysios,O'Brien-Jenkins Anne,Gimotty Phyllis A,Coukos George

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm1699.pdf

Reference50 articles.

1. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

2. Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 18538–18543 (2005).

3. Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 104, 3360–3365 (2007).

4. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).

5. Buckanovich, R.J. et al. Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol. Ther. 5, 635–642 (2006).

Cited by 470 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting amino acid-metabolizing enzymes for cancer immunotherapy;Frontiers in Immunology;2024-08-14

2. G protein‐coupled receptor‐mediated signaling of immunomodulation in tumor progression;The FASEB Journal;2024-07-17

3. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma;Nature Communications;2024-07-16

4. Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems;International Journal of Nanomedicine;2024-07

5. Milestones in tumor vascularization and its therapeutic targeting;Nature Cancer;2024-06-25